Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Considerations for Taking Oncology Care "to the Ends of the Earth": With D. Ross Camidge, MD, PhD; and Michael Smylie, MBBS, FRCPC

December 5th 2024

Drs Camidge and Smylie discussed Dr Smylie’s experience treating patients who live in the Northwest Territories of Canada.

Immune Profile Score Could Enhance Immunotherapy Decision-Making in Solid Tumors

December 4th 2024

Sandip P. Patel, MD, discusses the functionality of the IPS test and the potential role of IPS as a biomarker in clinical practice.

Toripalimab Plus Chemo Stands Alone as Preferred Frontline Regimen in Updated NCCN Guidelines for Advanced Nasopharyngeal Carcinoma

December 4th 2024

The NCCN has released updated guidelines for the management of nasopharyngeal carcinoma.

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

December 4th 2024

The FDA granted accelerated approval to zenocutuzumab for select patients with NSCLC and pancreatic adenocarcinoma with NRG1 fusions.

NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma

December 4th 2024

NICE has recommended the reimbursement for tebentafusp in HLA-A*02:01–positive unresectable or metastatic uveal melanoma.

TERN-701 Decreases BCR-ABL Levels, Generates Molecular Responses in R/R CML

December 4th 2024

TERN-701 reduced BCR-ABL levels and produced molecular responses in relapsed/refractory chronic myeloid leukemia.

Pancreatic Cancer Research Reveals Treatment Developments and Challenges: With John Strickler, MD

December 2nd 2024

Dr Strickler discusses the challenges of targeting RAS alterations in pancreatic cancer and efforts to improve pancreatic cancer screening rates.

IMNN-001 Plus Chemo Data Highlight Potential to Fill Unmet Need in Ovarian Cancer

December 2nd 2024

Premal Thaker, MD, MS, highlights data seen with the IL-12 Immunotherapy IMNN-001 in the OVATION-2 trial and next steps with the agent in ovarian cancer.

Eflornithine Plus Lomustine Demonstrates Clinically Meaningful Survival Benefits in Grade III IDH-Mutant Astrocytoma

December 2nd 2024

Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.

Targeted Therapies Remain Central to Ongoing Research in Pancreatic Cancer

November 30th 2024

Suneel Kamath, MD, shares insights on targeted therapies in pancreatic cancer after an X Takeover with OncLive during Pancreatic Cancer Awareness Month.

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

November 28th 2024

Dr Shaughnessy discusses the significance of the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

EC Approves Frontline Tislelizumab Plus Chemo for Advanced ESCC and Gastric/GEJ Cancer

November 27th 2024

Tislelizumab plus chemotherapy has been approved in Europe for first-line advanced ESCC and gastric/GEJ adenocarcinoma.

Adjuvant Ribociclib Wins EU Approval for HR+/HER2– Early Breast Cancer

November 27th 2024

Adjuvant ribociclib plus endocrine therapy was approved in Europe for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC

November 27th 2024

China’s NMPA has approved sacituzumab tirumotecan for pretreated unresectable locally advanced or metastatic triple-negative breast cancer.

Abequolixron/Docetaxel Produces Durable Responses in Recurrent Advanced NSCLC

November 27th 2024

Abequolixron plus docetaxel generated preliminary efficacy signals in the second- and third-line settings in recurrent advanced nonsquamous NSCLC.

MAXILUS Study Looks to Further Elucidate the Role of Luspatercept in MDS

November 26th 2024

The MAXILUS study will evaluate the maximum approved dose of luspatercept in lower-risk myelodysplastic syndrome.

China’s NMPA Accepts sNDA for Penpulimab Plus Anlotinib for Advanced HCC

November 26th 2024

China's NMPA has accepted a sNDA for penpulimab plus anlotinib for the first-line treatment of advanced hepatocellular carcinoma.

Lete-Cel Generates Durable Responses in Synovial Sarcoma and Myoxid/Round Cell Liposarcoma

November 26th 2024

Patients with metastatic myxoid/round cell liposarcoma or synovial sarcoma expressing NY-ESO-1 and HLA achieved an ORR of 42% with lete-cel.

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

November 25th 2024

Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.

FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma

November 25th 2024

The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.